<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PANTOPRAZOLE SODIUM- pantoprazole sodiumÂ tablet, delayed releaseÂ </strong><br>OrchidPharma Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Pantoprazole Sodium Delayed-Release Tablets, USP safely and effectively. See full prescribing information for Pantoprazole Sodium Delayed-Release Tablets, USP. <br><br>Pantoprazole Sodium Delayed-Release Tablets, USP <br>Initial U.S. approval: 2000</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration, Recommended Dosing Schedule (2.1) 12/2014<br>Contraindications (4) 12/2014<br>Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute Interstitial Nephritis</span> (5.3) 12/2014 </p>
<p class="Highlighta"> </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Pantoprazole sodium delayed-release tablets are a proton pump inhibitor indicated for the following: </p>
<ul class="Disc">
<li>Short-Term Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) (<a href="#INDICATIONSANDUSAGE11ShortTermTreatmentofErosiveEsophagitisAssociatedWithGastroesophagealRefluxDiseaseGERD">1.1</a>)</li>
<li>Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> (<a href="#INDICATIONSANDUSAGE12MaintenanceofHealingofErosiveEsophagitis">1.2</a>)</li>
<li>Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (<a href="#INDICATIONSANDUSAGE13PathologicalHypersecretoryConditionsIncludingZollingerEllisonSyndrome">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<a name="fgf"></a><table>
<thead><tr class="First Last" align="left" valign="top">
<th>Indication</th>
<th>Dose</th>
<th>Frequency</th>
</tr></thead>
<tbody>
<tr class="First" align="left" valign="top"><td><span class="Bold">Short-Term Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Associated With <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (2.1)</span></td></tr>
<tr align="left" valign="top">
<td>Adults</td>
<td>40 mg</td>
<td>Once Daily for up to 8 wks</td>
</tr>
<tr align="left" valign="top">
<td>Children (5 years and older)</td>
<td></td>
<td></td>
</tr>
<tr align="left" valign="top">
<td>â‰¥ 15 kg to &lt; 40 kg</td>
<td>20 mg</td>
<td>Once Daily for up to 8 wks</td>
</tr>
<tr align="left" valign="top">
<td>â‰¥ 40 kg</td>
<td>40 mg</td>
<td></td>
</tr>
<tr align="left" valign="top"><td>
<span class="Bold">Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </span><span class="Bold">(2.1)</span>
</td></tr>
<tr align="left" valign="top">
<td>Adults</td>
<td>40 mg</td>
<td>Once Daily*</td>
</tr>
<tr align="left" valign="top"><td>
<span class="Bold">Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome </span><span class="Bold">(2.1)</span>
</td></tr>
<tr class="Last" align="left" valign="top">
<td>Adults</td>
<td>40 mg</td>
<td>Twice Daily</td>
</tr>
</tbody>
</table>
<p class="Highlighta">* Controlled studies did not extend beyond 12 months  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">See full prescribing information for administration instructions  (<a href="#section-2">2</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Delayed-Release Tablets, 20 mg and 40 mg (<a href="#DOSAGE_FORMS_AND_STRENGTHS">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the formulation or to substituted benzimidazoles (<a href="#CONTRAINDICATIONS">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul>
<li>Symptomatic response does not preclude presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span> (5.1)</li>
<li><span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic gastritis</span> has been noted with long-term therapy (5.2)</li>
<li><span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute interstitial nephritis</span> has been observed in patients taking PPIs. (5.3)</li>
<li>Cyanocobalamin (vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> or a deficiency of cyanocobalamin. (5.4)</li>
<li>PPI therapy may be associated with increased risk of Clostridium difficile associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (5.5)</li>
<li>Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span>:Long-term and multiple daily dose PPI therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist or spine. (5.6)</li>
<li><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> has been reported rarely with prolonged treatment with PPIs (5.7)</li>
</ul>
<p class="Highlighta">  (<a href="#section-5">5</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most frequently occurring adverse reactions are as follows:  (<a href="#section-6">6</a>)</p>
<p class="Highlighta">  (<a href="#section-6">6</a>)</p>
<ul>
<li>For adult use (&gt;2%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>. (6)</li>
<li>For pediatric use (&gt;4%) are URI, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. (6)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact PROSAR at 866-562-4590 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Do not co-administer with atazanavir or nelfinavir (<a href="#DRUGINTERACTIONS71InterferencewithAntiretroviralTherapy">7.1</a>)</li>
<li>Concomitant warfarin use may require monitoring (<a href="#DRUGINTERACTIONS72CoumarinAnticoagulants">7.2</a>)</li>
<li>May interfere with the absorption of drugs where gastric pH is important for bioavailability (<a href="#DRUGINTERACTIONS74DrugsforWhichGastricpHCanAffectBioavailability">7.4</a>)</li>
<li>May produce false-positive urine screen for THC (<a href="#DRUGINTERACTIONS75FalsePositiveUrineTestsforTHC">7.5</a>)</li>
<li>Methotrexate: Pantoprazole may increase serum level of methotrexate (<a href="#DRUGINTERACTIONS76Methotrexate">7.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold"><span class="Bold">1.1 Short-Term Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Associated With <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</span></span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold"><span class="Bold">1.2 Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </span></span></a></h2>
<h2><a href="#section-1.3" class="toc"><span class="Bold"><span class="Bold">1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome </span></span></a></h2>
<h1><a href="#section-2" class="toc"> 2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 Recommended Dosing Schedule </span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Administration Instructions </span></a></h2>
<h1><a href="#section-3" class="toc"> 3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc"> 4 CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc"> 5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold"><span class="Bold">5.1 Concurrent <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span> </span></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold"><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic Gastritis</span> </span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold"><span class="Bold">5.3 <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute Interstitial Nephritis</span></span></span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold"><span class="Bold">5.4 Cyanocobalamin (Vitamin B-12) Deficiency</span></span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold"><span class="Bold">5.6 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></span></span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> </span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8 Tumorigenicity</span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9 Interference with Urine Screen for THC </span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.10 Concomitant use of Pantoprazole sodium with Methotrexate</span></a></h2>
<h1><a href="#section-6" class="toc"> 6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Trial Experience </span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Postmarketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"> 7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold"><span class="Bold">7.1 Interference with Antiretroviral Therapy</span></span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold"><span class="Bold">7.2 Coumarin Anticoagulants </span></span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.3 Clopidogrel </span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.4 Drugs for Which Gastric pH Can Affect Bioavailability </span></a></h2>
<h2><a href="#section-7.5" class="toc"><span class="Bold">7.5 False Positive Urine Tests for THC </span></a></h2>
<h2><a href="#section-7.6" class="toc"><span class="Bold">7.6 Methotrexate</span></a></h2>
<h1><a href="#section-8" class="toc"> 8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 Pregnancy </span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3 Nursing Mothers </span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4 Pediatric Use </span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5 Geriatric Use </span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold"><span class="Bold">8.6 Gender </span></span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold"><span class="Bold">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10 OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"> 11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc"> 12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 Mechanism of Action </span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold"><span class="Bold">12.2 Pharmacodynamics </span></span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 Pharmacokinetics </span></a></h2>
<h2><a href="#section-11.4" class="toc"><span class="Bold">12.4 Pharmacogenomics</span></a></h2>
<h1><a href="#section-12" class="toc"> 13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">13.2 Animal Toxicology and/or Pharmacology </span></a></h2>
<h1><a href="#section-13" class="toc"> 14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1 <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> (EE) Associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) </span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2 Long-Term Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></a></h2>
<h2><a href="#section-13.3" class="toc"><span class="Bold">14.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome </span></a></h2>
<h1><a href="#section-14" class="toc"> 16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc"></a></h2>
<h1><a href="#section-15" class="toc"><span class="Bold">17. PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Pantoprazole sodium delayed-release tablets are indicated for:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="INDICATIONSANDUSAGE11ShortTermTreatmentofErosiveEsophagitisAssociatedWithGastroesophagealRefluxDiseaseGERD"></a><a name="section-1.1"></a><p></p>
<h2><span class="Bold"><span class="Bold">1.1 Short-Term Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Associated With <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</span></span></h2>
<p class="First">Pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. For those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INDICATIONSANDUSAGE12MaintenanceofHealingofErosiveEsophagitis"></a><a name="section-1.2"></a><p></p>
<h2><span class="Bold"><span class="Bold">1.2 Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </span></span></h2>
<p class="First">Pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> and reduction in relapse rates of daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> symptoms in adult patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. Controlled studies did not extend beyond 12 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="INDICATIONSANDUSAGE13PathologicalHypersecretoryConditionsIncludingZollingerEllisonSyndrome"></a><a name="section-1.3"></a><p></p>
<h2><span class="Bold"><span class="Bold">1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome </span></span></h2>
<p class="First">Pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE_AND_ADMINISTRATION"></a><a name="section-2"></a><p></p>
<h1> 2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 Recommended Dosing Schedule </span></h2>
<p class="First">Pantoprazole sodium is supplied as delayed-release tablets. The recommended dosages are outlined in <a href="#gg">Table 1</a>.</p>
<a name="gg"></a><table>
<caption><span>Table 1: Recommended Dosing Schedule for Pantoprazole Sodium Delayed-Release Tablets</span></caption>
<thead><tr class="First Last">
<td><span class="Bold">Indication</span></td>
<td><span class="Bold">Dose</span></td>
<td><span class="Bold">Frequency</span></td>
</tr></thead>
<tbody>
<tr class="First"><td><span class="Bold">Short-Term Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Associated With <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></span></td></tr>
<tr>
<td>Adults</td>
<td>40 mg</td>
<td>Once daily for up to 8 weeks*</td>
</tr>
<tr>
<td>Children (5 years and older)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>â‰¥ 15 kg to &lt; 40 kg</td>
<td>20 mg</td>
<td>Once daily for up to 8 weeks</td>
</tr>
<tr>
<td>â‰¥ 40 kg</td>
<td>40 mg</td>
<td></td>
</tr>
<tr><td><span class="Bold">Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></td></tr>
<tr>
<td>Adults</td>
<td>40 mg</td>
<td>Once Daily***</td>
</tr>
<tr><td><span class="Bold">Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome</span></td></tr>
<tr class="Last">
<td>Adults</td>
<td>40 mg</td>
<td>Twice daily**</td>
</tr>
</tbody>
</table>
<p>* For adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered.</p>
<p>** Dosage regimens should be adjusted to individual patient needs and should continue for as long as clinically indicated. Doses up to 240 mg daily have been administered.</p>
<p style="border-left:1px solid;"><span class="XmChange">*** Controlled studies did not extend beyond 12 months</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Administration Instructions </span></h2>
<p class="First">Directions for method of administration for each dosage form are presented in <a href="#cftrs">Table 2</a>.</p>
<a name="t2"></a><table>
<caption><span></span></caption>
<tbody class="Headless">
<tr class="First Last">
<td><p class="First"><span class="Bold">Formulation</span></p></td>
<td align="center"><span class="Bold">RouteÂ </span></td>
<td><span class="Bold">Â Instructions*</span></td>
</tr>
<tr class="First Last">
<td><span class="Bold">Delayed-Release Tablets</span></td>
<td align="center">Oral</td>
<td>Swallowed whole, with or without food</td>
</tr>
</tbody>
</table>
<p>* Patients should be cautioned that pantoprazole sodium delayed-release tablets should not be split, chewed, or crushed.</p>
<p><span class="Underline">Pantoprazole Sodium Delayed-Release Tablets</span><br>Pantoprazole sodium delayed-release tablets should be swallowed whole, with or without food in the stomach. If patients are unable to swallow a 40 mg tablet, two 20 mg tablets may be taken. Concomitant administration of antacids does not affect the absorption of pantoprazole sodium delayed-release tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="DOSAGE_FORMS_AND_STRENGTHS"></a><a name="section-3"></a><p></p>
<h1> 3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">Delayed-Release Tablets:</p>
<ul class="Disc">
<li>40 mg, yellow colored, oval shaped, enteric coated tablets imprinted with â€œ40â€? on one side and plain on the other side.</li>
<li>20 mg, yellow colored, oval shaped, enteric coated tablets imprinted with â€œ20â€? on one side and plain on the other side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1> 4 CONTRAINDICATIONS </h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Pantoprazole is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the formulation or any substituted benzimidazole. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> [<span class="Italics">see Adverse Reactions (6)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1> 5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGSANDPRECAUTIONS51ConcurrentGastricMalignancy"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold"><span class="Bold">5.1 Concurrent <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span> </span></span></h2>
<p class="First">Symptomatic response to therapy with pantoprazole does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGSANDPRECAUTIONS52AtrophicGastritis"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold"><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic Gastritis</span> </span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic gastritis</span> has been noted occasionally in gastric corpus biopsies from patients treated long-term with pantoprazole, particularly in patients who were <span class="Italics">H. pylori</span> positive.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2><span class="Bold"><span class="Bold">5.3 <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute Interstitial Nephritis</span></span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute interstitial nephritis</span> has been observed in patients taking PPIs including pantoprazole. <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute interstitial nephritis</span> may occur at any point during PPI therapy and is generally attributed to an idiopathic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Discontinue pantoprazole if <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span> develops <span class="Italics">[see Contraindications (4)]</span><span class="XmChange">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2><span class="Bold"><span class="Bold">5.4 Cyanocobalamin (Vitamin B-12) Deficiency</span></span></h2>
<p class="First">Generally, daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> of cyanocobalamin (Vitamin B-12) caused by hypo- or <span class="product-label-link" type="condition" conceptid="193804" conceptname="Achlorhydria">achlorhydria</span>. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lef6345bc-69fd-4f2b-b064-9eabd5c8b7b9"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5 <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></span></h2>
<p class="First">Published observational studies suggest that PPI therapy like pantoprazole may be associated with an increased risk of Clostridium difficile associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, especially in hospitalized patients. This diagnosis should be considered for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not improve <span class="Italics">[see Adverse Reactions (6.2)]</span>.</p>
<p>Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGSANDPRECAUTIONS54BoneFracture"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold"><span class="Bold">5.6 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></span></span></h2>
<p class="First">Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> should be managed according to established treatment guidelines [<span class="Italics">see Dosage and Administration (<a href="#DOSAGE_AND_ADMINISTRATION">2</a>) and Adverse Reactions (<a href="#ADVERSE_REACTIONS">6.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGSANDPRECAUTIONS55Hypomagnesemia"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> </span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In most patients, treatment of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> required magnesium replacement and discontinuation of the PPI.</p>
<p>For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodicallyÂ [<span class="Italics">see Adverse Reactions (6.2)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2><span class="Bold">5.8 Tumorigenicity</span></h2>
<p class="First">Due to the chronic nature of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, there may be a potential for prolonged administration of pantoprazole. In long-term rodent studies, pantoprazole was carcinogenic and caused rare types of gastrointestinal tumors. The relevance of these findings to tumor development in humans is unknownÂ [<span class="Italics">see Nonclinical Toxicology (13.1)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2><span class="Bold">5.9 Interference with Urine Screen for THC </span></h2>
<p class="First">See <span class="Italics">Drug Interactions (7.5).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WARNINGSANDPRECAUTIONS58ConcomitantuseofPantoprazolesodiumwithMethotrexate"></a><a name="section-5.10"></a><p></p>
<h2><span class="Bold">5.10 Concomitant use of Pantoprazole sodium with Methotrexate</span></h2>
<p class="First">Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patientsÂ [<span class="Italics">see Drug Interactions (7.6)</span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1> 6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Trial Experience </span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Adults</span></h3>
<p class="First">Safety in nine randomized comparative U.S. clinical trials in patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> included 1,473 patients on oral pantoprazole (20 mg or 40 mg), 299 patients on an H2-receptor antagonist, 46 patients on another proton pump inhibitor, and 82 patients on placebo. The most frequently occurring adverse reactions are listed inÂ <a href="#t3">Table 3.</a></p>
<a name="t3"></a><table>
<caption><span>Table 3: Adverse Reactions Reported in Clinical Trials of Adult Patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> at a Frequency of &gt; 2%</span></caption>
<thead><tr class="First Last">
<td></td>
<td align="center">Pantoprazole <br> (n=1473)<br>%</td>
<td align="center">Comparators<br> (n=345)<br>%</td>
<td align="center">Placebo<br> (n=82)<br>%</td>
</tr></thead>
<tbody>
<tr class="First">
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">12.2</td>
<td align="center">12.8</td>
<td align="center">8.5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">8.8</td>
<td align="center">9.6</td>
<td align="center">4.9</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">7</td>
<td align="center">5.2</td>
<td align="center">9.8</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">6.2</td>
<td align="center">4.1</td>
<td align="center">6.1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">4.3</td>
<td align="center">3.5</td>
<td align="center">2.4</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center">3.9</td>
<td align="center">2.9</td>
<td align="center">3.7</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">3</td>
<td align="center">2.9</td>
<td align="center">1.2</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">2.8</td>
<td align="center">1.4</td>
<td align="center">1.2</td>
</tr>
</tbody>
</table>
<p>Additional adverse reactions that were reported for pantoprazole sodium in clinical trials with a frequency of â‰¤ 2% are listed below by body system:</p>
<p><span class="Underline">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p><span class="Underline">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p><span class="Underline">Hematologic</span>: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Underline">Metabolic/Nutritional</span>: elevated CK (creatine kinase), <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, elevated triglycerides, liver enzymes elevated</p>
<p><span class="Underline">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Underline">Nervous</span>: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Underline">Skin and Appendages</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Underline">Special Senses</span> : <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></p>
<p><span class="Bold">Pediatric Patients</span></p>
<p>Safety of pantoprazole in the treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> (EE) associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> was evaluated in pediatric patients ages 1 year through 16 years in three clinical trials. Safety trials involved pediatric patients with EE; however, as EE is uncommon in the pediatric population, 249 pediatric patients with endoscopically-proven or symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> were also evaluated. All adult adverse reactions to pantoprazole are considered relevant to pediatric patients. In patients ages 1 year through 16 years, the most commonly reported (&gt; 4%) adverse reactions include: URI, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p>For safety information in patients less than 1 year of age see <span class="Italics">Use in Specific Populations (8.4)</span>.</p>
<p>Additional adverse reactions that were reported for pantoprazole in pediatric patients in clinical trials with a frequency of â‰¤ 4% are listed below by body system:</p>
<p><span class="Underline">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p><span class="Underline">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p>
<p><span class="Underline">Metabolic/Nutritional</span>: elevated triglycerides, elevated liver enzymes, elevated CK (creatine kinase)</p>
<p><span class="Underline">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Underline">Nervous</span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Underline">Skin and Appendages</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p>The following adverse reactions seen in adults in clinical trials were not reported in pediatric patients in clinical trials, but are considered relevant to pediatric patients: <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Zollinger-Ellison Syndrome</span></h3>
<p class="First">In clinical studies of Zollinger-Ellison Syndrome, adverse reactions reported in 35 patients taking pantoprazole 80 mg/day to 240 mg/day for up to 2 years were similar to those reported in adult patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Postmarketing Experience</span></h2>
<p class="First">The following adverse reactions have been identified during postapproval use of pantoprazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>These adverse reactions are listed below by body system:</p>
<br><p><span class="Underline">General Disorders and Administration Conditions</span>: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p><span class="Underline">Hematologic</span>: <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span></p>
<p><span class="Underline">Hepatobiliary Disorders</span>: <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span> leading to <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>)</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p><span class="Underline">Investigations</span>: weight changes</p>
<p><span class="Underline">Metabolism and Nutritional Disorders</span>: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span></p>
<p><span class="Underline">Nervous</span>: <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">ageusia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span></p>
<p><span class="Underline">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Underline">Renal and Urinary Disorders</span>: interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p><span class="Underline">Skin and Subcutaneous Tissue Disorders</span>: severe dermatologic reactions (some fatal), including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN, some fatal), and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (Quinckeâ€™s <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>)</p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1> 7 DRUG INTERACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="DRUGINTERACTIONS71InterferencewithAntiretroviralTherapy"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold"><span class="Bold">7.1 Interference with Antiretroviral Therapy</span></span></h2>
<p class="First">Concomitant use of atazanavir or nelfinavir with proton pump inhibitors is not recommended. Co-administration of atazanavir or nelfinavir with proton pump inhibitors is expected to substantially decrease atazanavir or nelfinavir plasma concentrations and may result in a loss of therapeutic effect and development of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DRUGINTERACTIONS72CoumarinAnticoagulants"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold"><span class="Bold">7.2 Coumarin Anticoagulants </span></span></h2>
<p class="First">There have been postmarketing reports of increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold">7.3 Clopidogrel </span></h2>
<p class="First">Concomitant administration of pantoprazole and clopidogrel in healthy subjects had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition [<span class="Italics">see </span><span class="Italics">Clinical Pharmacology (<a href="#CLINICALPHARMACOLOGYPHARMACOKINETICS">12.3</a>)</span>]<span class="Italics">.</span> No dose adjustment of clopidogrel is necessary when administered with an approved dose of pantoprazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DRUGINTERACTIONS74DrugsforWhichGastricpHCanAffectBioavailability"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">7.4 Drugs for Which Gastric pH Can Affect Bioavailability </span></h2>
<p class="First">Due to its effects on gastric acid secretion, pantoprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, ampicillin esters, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease.</p>
<p>Co-administration of pantoprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving pantoprazole and MMF. Use pantoprazole with caution in transplant patients receiving MMF <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DRUGINTERACTIONS75FalsePositiveUrineTestsforTHC"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">7.5 False Positive Urine Tests for THC </span></h2>
<p class="First">There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving proton pump inhibitors. An alternative confirmatory method should be considered to verify positive results.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DRUGINTERACTIONS76Methotrexate"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">7.6 Methotrexate</span></h2>
<p class="First">Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of Methotrexate with PPIs have been conducted <span class="Italics">[see Warnings and Precautions (5.10)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1> 8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1 Pregnancy </span></h2>
<p class="First"><span class="Bold">Teratogenic Effects</span><br><span class="Italics"><span class="Bold">Pregnancy Category B</span></span><br>Reproduction studies have been performed in rats at oral doses up to 88 times the recommended human dose and in rabbits at oral doses up to 16 times the recommended human dose and have revealed no evidence of impaired fertility or harm to the fetus due to pantoprazole. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed [<span class="Italics">see Nonclinical Toxicology (13.2)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.3 Nursing Mothers </span></h2>
<p class="First">Pantoprazole and its metabolites are excreted in the milk of rats. Pantoprazole excretion in human milk has been detected in a study of a single nursing mother after a single 40 mg oral dose. The clinical relevance of this finding is not known. Many drugs which are excreted in human milk have a potential for serious adverse reactions in nursing infants. Based on the potential for tumorigenicity shown for pantoprazole in rodent carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.4 Pediatric Use </span></h2>
<p class="First">The safety and effectiveness of pantoprazole for short-term treatment (up to eight weeks) of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> (EE) associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> have been established in pediatric patients 1 year through 16 years of age. Effectiveness for EE has not been demonstrated in patients less than 1 year of age. In addition, for patients less than 5 years of age, there is no appropriate dosage strength in an age-appropriate formulation available. Therefore, pantoprazole is indicated for the short-term treatment of EE associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> for patients 5 years and older. The safety and effectiveness of pantoprazole for pediatric uses other than EE have not been established.</p>
<p><span class="Italics"><span class="Bold">1 year through 16 years of age</span></span></p>
<p>Use of pantoprazole in pediatric patients 1 year through 16 years of age for short-term treatment (up to eight weeks) of EE associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> is supported by: a) extrapolation of results from adequate and well-controlled studies that supported the approval of pantoprazole for treatment of EE associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in adults, and b) safety, effectiveness, and pharmacokinetic studies performed in pediatric patients <span class="Italics">[see Clinical Studies (14.1), and Clinical Pharmacology (12.3)]</span>.</p>
<p>Safety of pantoprazole in the treatment of EE associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in pediatric patients 1 through 16 years of age was evaluated in three multicenter, randomized, double-blind, parallel-treatment studies, involving 249 pediatric patients, including 8 with EE (4 patients ages 1 year to 5 years and 4 patients 5 years to 11 years). The children ages 1 year to 5 years with endoscopically diagnosed EE (defined as an endoscopic Hetzel-Dent score â‰¥ 2) were treated once daily for 8 weeks with one of two dose levels of pantoprazole (approximating 0.6 mg/kg or 1.2 mg/kg). All 4 of these patients with EE were healed (Hetzel-Dent score of 0 or 1) at 8 weeks. Because EE is uncommon in the pediatric population, predominantly pediatric patients with endoscopically-proven or symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> were also included in these studies. Patients were treated with a range of doses of pantoprazole once daily for 8 weeks. For safety findings see Adverse Reactions (6.1). Because these pediatric trials had no placebo, active comparator, or evidence of a dose response, the trials were inconclusive regarding the clinical benefit of pantoprazole for symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in the pediatric population. The effectiveness of pantoprazole for treating symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in pediatric patients has not been established.</p>
<p>Although the data from the clinical trials support use of pantoprazole for the short-term treatment of EE associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in pediatric patients 1 year through 5 years, there is no commercially available dosage formulation appropriate for patients less than 5 years of age <span class="Italics">[see Dosage and Administration (2)]</span>.</p>
<p>In a population pharmacokinetic analysis, clearance values in the children 1 to 5 years old with endoscopically proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> had a median value of 2.4 L/h. Following a 1.2 mg/kg equivalent dose (15 mg for â‰¤ 12.5 kg and 20 mg for &gt; 12.5 to &lt; 25 kg), the plasma concentrations of pantoprazole were highly variable and the median time to peak plasma concentration was 3 to 6 hours. The estimated AUC for patients 1 to 5 years old was 37% higher than for adults receiving a single 40 mg tablet, with a geometric mean AUC value of 6.8 mcgâ€¢hr/mL.</p>
<p><span class="Italics"><span class="Bold">Neonates to less than one year of age</span></span></p>
<p>Pantoprazole was not found to be effective in a multicenter, randomized, double-blind, placebo-controlled, treatment-withdrawal study of 129 pediatric patients 1 through 11 months of age. Patients were enrolled if they had symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> based on medical history and had not responded to non-pharmacologic interventions for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> for two weeks. Patients received pantoprazole daily for four weeks in an open-label phase, then patients were randomized in equal proportion to receive pantoprazole treatment or placebo for the subsequent four weeks in a double-blind manner. Efficacy was assessed by observing the time from randomization to study discontinuation due to symptom worsening during the four-week treatment-withdrawal phase. There was no statistically significant difference between pantoprazole and placebo in the rate of discontinuation.</p>
<p>In this trial, the adverse reactions that were reported more commonly (difference of â‰¥ 4%) in the treated population compared to the placebo population were elevated CK, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, and <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>.</p>
<p>In a population pharmacokinetic analysis, the systemic exposure was higher in patients less than 1 year of age with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> compared to adults who received a single 40 mg dose (geometric mean AUC was 103% higher in preterm infants and neonates receiving single dose of 2.5 mg of pantoprazole, and 23% higher in infants 1 through 11 months of age receiving a single dose of approximately 1.2 mg/kg). In these patients, the apparent clearance (CL/F) increased with age (median clearance: 0.6 L/hr, range: 0.03 to 3.2 L/hr).</p>
<p>These doses resulted in pharmacodynamic effects on gastric but not esophageal pH. Following once daily dosing of 2.5 mg of pantoprazole in preterm infants and neonates, there was an increase in the mean gastric pH (from 4.3 at baseline to 5.2 at steady-state) and in the mean % time that gastric pH was &gt; 4 (from 60% at baseline to 80% at steady-state). Following once daily dosing of approximately 1.2 mg/kg of pantoprazole in infants 1 through 11 months of age, there was an increase in the mean gastric pH (from 3.1 at baseline to 4.2 at steady-state) and in the mean % time that gastric pH was &gt; 4 (from 32% at baseline to 60% at steady-state). However, no significant changes were observed in mean intraesophageal pH or % time that esophageal pH was &lt; 4 in either age group.</p>
<p>Because pantoprazole was not shown to be effective in the randomized, placebo-controlled study in this age group, the use of pantoprazole for treatment of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in infants less than 1 year of age is not indicated.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.5 Geriatric Use </span></h2>
<p class="First">In short-term U.S. clinical trials, <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> healing rates in the 107 elderly patients (â‰¥ 65 years old) treated with pantoprazole were similar to those found in patients under the age of 65. The incidence rates of adverse reactions and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2><span class="Bold"><span class="Bold">8.6 Gender </span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive esophagitis</span> healing rates in the 221 women treated with pantoprazole sodium delayed-release tablets in U.S. clinical trials were similar to those found in men. In the 122 women treated long-term with pantoprazole 40 mg or 20 mg, healing was maintained at a rate similar to that in men. The incidence rates of adverse reactions were also similar for men and women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2><span class="Bold"><span class="Bold">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></span></h2>
<p class="First">Doses higher than 40 mg/day have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see Clinical Pharmacology (<a href="#CLINICALPHARMACOLOGYPHARMACOKINETICS">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10 OVERDOSAGE</span></h1>
<p class="First">Experience in patients taking very high doses of pantoprazole (&gt; 240 mg) is limited. Spontaneous post-marketing reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are generally within the known safety profile of pantoprazole.</p>
<p>Pantoprazole is not removed by hemodialysis. In case of overdosage, treatment should be symptomatic and supportive.</p>
<p>Single oral doses of pantoprazole at 709 mg/kg, 798 mg/kg, and 887 mg/kg were lethal to mice, rats, and dogs, respectively. The symptoms of acute toxicity were <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DESCRIPTION"></a><a name="section-10"></a><p></p>
<h1> 11 DESCRIPTION</h1>
<p class="First">The active ingredient in pantoprazole sodium delayed-release tablets, USP is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion. Its molecular formula is C<span class="Sub">16</span>H<span class="Sub">14</span>F<span class="Sub">2</span>N<span class="Sub">3</span>NaO<span class="Sub">4</span>S x 1.5 H<span class="Sub">2</span>O, with a molecular weight of 432.4. The structural formula is:</p>
<div class="Figure"><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d132d29d-723e-4357-87f2-0d760afa50a4&amp;name=pantoprazole-sodium--figure-1.jpg"></div>
<p>Pantoprazole sodium sesquihydrate is a white to off-white crystalline powder and is racemic. Pantoprazole has weakly basic and acidic properties. Pantoprazole sodium sesquihydrate is freely soluble in water, methanol and dehydrated alcohol, very slightly soluble in phosphate buffer at pH 7.4, and practically insoluble in hexane and dichloromethane.</p>
<p>The stability of the compound in aqueous solution is pH-dependent. The rate of degradation increases with decreasing pH. At ambient temperature, the degradation half-life is approximately 2.8 hours at pH 5 and approximately 220 hours at pH 7.8.</p>
<p>Pantoprazole sodium, USP is supplied as a delayed-release tablet, available in two strengths (20 mg and 40 mg).</p>
<p>Each pantoprazole sodium delayed-release tablet, USP contains 45.1 mg or 22.56 mg of pantoprazole sodium sesquihydrate (equivalent to 40 mg or 20 mg pantoprazole, respectively) with the following inactive ingredients: calcium stearate, crospovidone, hydroxypropyl cellulose, hypromellose, mannitol, methacrylic acid co-polymer dispersion, opacode black, opadry yellow, sodium carbonate, talc, and triethyl citrate.</p>
<p>The components of opacode black are ammonium hydroxide, iron oxide black, isopropyl alcohol, n-butyl alcohol, propylene glycol and shellac glaze in ethanol, and the components of opadry yellow are hypromellose, iron oxide yellow, polyethylene glycol 6000 and titanium dioxide.</p>
<p>Pantoprazole sodium delayed-release tablets, USP (40 mg and 20 mg) complies with USP dissolution test 3.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1> 12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold">12.1 Mechanism of Action </span></h2>
<p class="First">Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H<span class="Sup">+</span>, K<span class="Sup">+</span>)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H<span class="Sup">+</span>, K<span class="Sup">+</span>)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold"><span class="Bold">12.2 Pharmacodynamics </span></span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<h3>Antisecretory Activity</h3>
<p class="First">Under maximal acid stimulatory conditions using pentagastrin, a dose-dependent decrease in gastric acid output occurs after a single dose of oral (20 to 80 mg) or a single dose of intravenous (20 to 120 mg) pantoprazole in healthy volunteers. Pantoprazole given once daily results in increasing inhibition of gastric acid secretion. Following the initial oral dose of 40 mg pantoprazole, a 51% mean inhibition was achieved by 2.5 hours. With once-a-day dosing for 7 days, the mean inhibition was increased to 85%. Pantoprazole suppressed acid secretion in excess of 95% in half of the subjects. Acid secretion had returned to normal within a week after the last dose of pantoprazole; there was no evidence of rebound hypersecretion.</p>
<p>In a series of dose-response studies, pantoprazole, at oral doses ranging from 20 to 120 mg, caused dose-related increases in median basal gastric pH and in the percent of time gastric pH was &gt; 3 and &gt; 4. Treatment with 40 mg of pantoprazole produced significantly greater increases in gastric pH than the 20 mg dose. Doses higher than 40 mg (60, 80, 120 mg) did not result in further significant increases in median gastric pH. The effects of pantoprazole on median pH from one double-blind crossover study are shown inÂ <a href="#asqweq">Table 4</a>.</p>
<a name="t4"></a><table>
<caption><span>Table 4: Effect of Single Daily Doses of Oral Pantoprazole on Intragastric pH</span></caption>
<thead><tr class="First Last">
<td></td>
<td><span class="Bold">Median pH on day 7</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td>Time</td>
<td>Placebo</td>
<td>20 mg</td>
<td>40 mg</td>
<td>80 mg</td>
</tr>
<tr>
<td>
<p class="First">8 a.m. to 8 a.m.</p>
<p>(24 hours)</p>
</td>
<td>1.3</td>
<td>2.9*</td>
<td>3.8*#</td>
<td>3.9*#</td>
</tr>
<tr>
<td>8 a.m. to 10 p.m.<p class="First">(Daytime)</p>
</td>
<td>1.6</td>
<td>3.2*</td>
<td>4.4*#</td>
<td>4.8*#</td>
</tr>
<tr class="Last">
<td>10 p.m. to 8 a.m.<p class="First">(Nighttime)</p>
</td>
<td>1.2</td>
<td>2.1*</td>
<td>3*</td>
<td>2.6*</td>
</tr>
</tbody>
</table>
<p>*Significantly different from placebo</p>
<p># Significantly different from 20 mg</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<h3>Serum Gastrin Effects</h3>
<p class="First">Fasting serum gastrin levels were assessed in two double-blind studies of the acute healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> (EE) in which 682 patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) received 10, 20, or 40 mg of pantoprazole for up to 8 weeks. At 4 weeks of treatment there was an increase in mean gastrin levels of 7%, 35%, and 72% over pretreatment values in the 10, 20, and 40 mg treatment groups, respectively. A similar increase in serum gastrin levels was noted at the 8 week visit with mean increases of 3%, 26%, and 84% for the three pantoprazole dose groups. Median serum gastrin levels remained within normal limits during maintenance therapy with pantoprazole sodium delayed-release tablets.</p>
<p>In long-term international studies involving over 800 patients, a 2 to 3 fold mean increase from the pretreatment fasting serum gastrin level was observed in the initial months of treatment with pantoprazole at doses of 40 mg per day during <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> maintenance studies and 40 mg or higher per day in patients with refractory <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. Fasting serum gastrin levels generally remained at approximately 2 to 3 times baseline for up to 4 years of periodic follow-up in clinical trials.</p>
<p>Following short-term treatment with pantoprazole, elevated gastrin levels return to normal by at least 3 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<h3>Enterochromaffin-Like (ECL) Cell Effects</h3>
<p class="First">In 39 patients treated with oral pantoprazole 40 mg to 240 mg daily (majority receiving 40 mg to 80 mg) for up to 5 years, there was a moderate increase in ECL-cell density, starting after the first year of use, which appeared to plateau after 4 years.</p>
<p>In a nonclinical study in Sprague-Dawley rats, lifetime exposure (24 months) to pantoprazole at doses of 0.5 to 200 mg/kg/day resulted in dose-related increases in gastric ECL cell proliferation and gastric neuroendocrine (NE)-cell tumors. Gastric NE-cell tumors in rats may result from chronic elevation of serum gastrin concentrations. The high density of ECL cells in the rat stomach makes this species highly susceptible to the proliferative effects of elevated gastrin concentrations produced by proton pump inhibitors. However, there were no observed elevations in serum gastrin following the administration of pantoprazole at a dose of 0.5 mg/kg/day. In a separate study, a gastric NE-cell tumor without concomitant ECL-cell proliferative changes was observed in 1 female rat following 12 months of dosing with pantoprazole at 5 mg/kg/day and a 9 month off-dose recovery [<span class="Italics">see Nonclinical Toxicology (<a href="#NONCLINICALTOXICOLOGYCARCINOGENESISANDMUTAGENESISANDIMPAIRMENTOFFERTILITY">13.1</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="CLINICALPHARMACOLOGYPHARMACOKINETICS"></a><a name="section-11.3"></a><p></p>
<h2><span class="Bold">12.3 Pharmacokinetics </span></h2>
<p class="First">Pantoprazole sodium delayed-release tablets are prepared as enteric-coated tablets so that absorption of pantoprazole begins only after the tablet leaves the stomach. Peak serum concentration (Cmax) and area under the serum concentration time curve (AUC) increase in a manner proportional to oral and intravenous doses from 10 mg to 80 mg. Pantoprazole does not accumulate, and its pharmacokinetics are unaltered with multiple daily dosing. Following oral or intravenous administration, the serum concentration of pantoprazole declines biexponentially, with a terminal elimination half-life of approximately one hour.</p>
<p>In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (Cmax) is 2.5 mcg/mL; the time to reach the peak concentration (tmax) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcgâ€¢h/mL (range 1.4 to 13.3 mcgâ€¢h/mL). Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">After administration of a single or multiple oral 40 mg doses of pantoprazole sodium delayed-release tablets, the peak plasma concentration of pantoprazole was achieved in approximately 2.5 hours, and C<span class="Sub">max</span> was 2.5 mcg/mL. Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%. Pantoprazole absorption is not affected by concomitant administration of antacids.</p>
<p>Administration of pantoprazole sodium delayed-release tablets with food may delay its absorption up to 2 hours or longer; however, the Cmax and the extent of pantoprazole absorption (AUC) are not altered. Thus, pantoprazole sodium delayed-release tablets may be taken without regard to timing of meals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid. The serum protein binding of pantoprazole is about 98%, primarily to albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">After a single oral or intravenous dose of <span class="Sup">14</span>C-labeled pantoprazole to healthy, normal metabolizer volunteers, approximately 71% of the dose was excreted in the urine, with 18% excreted in the feces through biliary excretion. There was no renal excretion of unchanged pantoprazole.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-11.3.5"></a><p></p>
<h3>Geriatric</h3>
<p class="First">Only slight to moderate increases in pantoprazole AUC (43%) and C<span class="Sub">max</span> (26%) were found in elderly volunteers (64 to 76 years of age) after repeated oral administration, compared with younger subjects. No dosage adjustment is recommended based on age.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-11.3.6"></a><p></p>
<h3>Pediatric</h3>
<p class="First">The pharmacokinetics of pantoprazole were studied in children less than 16 years of age in four randomized, open-label clinical trials in pediatric patients with presumed/proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. A pediatric granule formulation was studied in children through 5 years of age, and pantoprazole sodium delayed-release tablets were studied in children older than 5 years.</p>
<p>In a population PK analysis, total clearance increased with increasing bodyweight in a non-linear fashion. The total clearance also increased with increasing age only in children under 3 years of age.</p>
<p><span class="Underline">Neonate through 5 years of age</span></p>
<p>See <span class="Italics">Use in Specific Populations (8.4)</span>.</p>
<p><span class="Underline">Children and Adolescents 6 through 16 Years of Age</span></p>
<p>The pharmacokinetics of pantoprazole sodium delayed-release tablets were evaluated in children ages 6 through 16 years with a clinical diagnosis of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. The PK parameters following a single oral dose of 20 mg or 40 mg of pantoprazole sodium delayed-release tablets in children ages 6 through 16 years were highly variable (%CV ranges 40 to 80%). The geometric mean AUC estimated from population PK analysis after a 40 mg pantoprazole tablet in pediatric patients was about 39% and 10% higher respectively in 6 to 11 and 12 to 16 year-old children, compared to that of adults (Table 6).</p>
<a name="tab"></a><table width="100%">
<caption><span>Table 6: PK Parameters in Children and Adolescents 6 through 16 years with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> receiving 40 mg Pantoprazole Sodium Delayed-Release Tablets</span></caption>
<tbody class="Headless">
<tr class="First">
<td></td>
<td><span class="Bold">Â 6 to 11 years (n=12)</span></td>
<td><span class="Bold">12 to 16 years (n=11)Â </span></td>
</tr>
<tr>
<td>Cmax (mcg/mL)<span class="Sup">a</span>
</td>
<td>Â 1.8</td>
<td>Â 1.8</td>
</tr>
<tr>
<td>Â tmax (h)<span class="Sup">b</span>
</td>
<td>Â 2</td>
<td>Â 2</td>
</tr>
<tr>
<td>Â AUC (mcgâ€¢h/mL)<span class="Sup">a</span>
</td>
<td>Â 6.9</td>
<td>Â 5.5</td>
</tr>
<tr class="Last">
<td>Â CL/F (L/h)<span class="Sup">b</span>
</td>
<td>Â 6.6</td>
<td>Â 6.8</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Geometric mean values</p>
<p><span class="Sup">b</span> Median values</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<h3>Gender</h3>
<p class="First">There is a modest increase in pantoprazole AUC and Cmax in women compared to men. However, weight-normalized clearance values are similar in women and men. No dosage adjustment is recommended based on gender. In pediatric patients ages 1 through 16 years there were no clinically relevant effects of gender on clearance of pantoprazole, as shown by population pharmacokinetic analysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, pharmacokinetic parameters for pantoprazole were similar to those of healthy subjects. No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or in patients undergoing hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.9"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First">In patients with mild to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh A to C cirrhosis), maximum pantoprazole concentrations increased only slightly (1.5 fold) relative to healthy subjects. Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted. These pharmacokinetic changes in hepatic-impaired patients result in minimal drug accumulation following once-daily, multiple-dose administration. No dosage adjustment is needed in patients with mild to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Doses higher than 40 mg/day have not been studied in hepatically impaired patients.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-11.3.10"></a><p></p>
<h3>Drug-Drug Interactions</h3>
<p class="First">Pantoprazole is metabolized mainly by CYP2C19 and to minor extents by CYPs 3A4, 2D6, and 2C9. In in vivo drug-drug interaction studies with CYP2C19 substrates (diazepam [also a CYP3A4 substrate] and phenytoin [also a CYP3A4 inducer] and clopidogrel), nifedipine, midazolam, and clarithromycin (CYP3A4 substrates), metoprolol (a CYP2D6 substrate), diclofenac, naproxen and piroxicam (CYP2C9 substrates), and theophylline (a CYP1A2 substrate) in healthy subjects, the pharmacokinetics of pantoprazole were not significantly altered.</p>
<p>Clopidogrel: Clopidogrel is metabolized to its active metabolite in part by CYP2C19. In a crossover clinical study, 66 healthy subjects were administered clopidogrel (300 mg loading dose followed by 75 mg per day) alone and with pantoprazole (80 mg at the same time as clopidogrel) for 5 days. On Day 5, the mean AUC of the active metabolite of clopidogrel was reduced by approximately 14% (geometric mean ratio was 86%, with 90% CI of 79 to 93%) when pantoprazole was coadministered with clopidogrel as compared to clopidogrel administered alone. Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation (induced by 5 Î¼M ADP) was correlated with the change in the exposure to clopidogrel active metabolite. The clinical significance of this finding is not clear.</p>
<p>Mycophenolate Mofetil (MMF): Administration of pantoprazole 40 mg twice daily for 4 days and a single 1000 mg dose of MMF approximately one hour after the last dose of pantoprazole to 12 healthy subjects in a cross-over study resulted in a 57% reduction in the Cmax and 27% reduction in the AUC of MPA. Transplant patients receiving approximately 2000 mg per day of MMF (n=12) were compared to transplant patients receiving approximately the same dose of MMF and pantoprazole 40 mg per day (n=21). There was a 78% reduction in the Cmax and a 45% reduction in the AUC of MPA in patients receiving both pantoprazole and MMF.</p>
<p><span class="Italics">In vivo</span> studies also suggest that pantoprazole does not significantly affect the kinetics of the following drugs (cisapride, theophylline, diazepam [and its active metabolite, desmethyldiazepam], phenytoin, warfarin, metoprolol, nifedipine, carbamazepine, midazolam, clarithromycin, naproxen, piroxicam, and oral contraceptives [levonorgestrel/ethinyl estradiol]). Dosage adjustment of these drugs is not necessary when they are coadministered with pantoprazole. In other in vivo studies, digoxin, ethanol, glyburide, antipyrine, caffeine, metronidazole, and amoxicillin had no clinically relevant interactions with pantoprazole.</p>
<p>Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.</p>
<p>There was also no interaction with concomitantly administered antacids.</p>
<p>There have been postmarketing reports of increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly [<span class="Italics">see Drug Interactions (<a href="#DRUGINTERACTIONS72CoumarinAnticoagulants">7.2</a>)</span>].</p>
<p>Although no significant drug-drug interactions have been observed in clinical studies, the potential for significant drug-drug interactions with more than once-daily dosing with high doses of pantoprazole has not been studied in poor metabolizers or individuals who are hepatically impaired.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.11"></a><p></p>
<h3>Other Effects</h3>
<p class="First">In a clinical pharmacology study, pantoprazole 40 mg given once daily for 2 weeks had no effect on the levels of the following hormones: cortisol, testosterone, triiodothyronine (T<span class="Sub">3</span>), thyroxine (T<span class="Sub">4</span>), thyroid-stimulating hormone (TSH), thyronine-binding protein, parathyroid hormone, insulin, glucagon, renin, aldosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, and growth hormone.</p>
<p>In a 1 year study of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> patients treated with pantoprazole 40 mg or 20 mg, there were no changes from baseline in overall levels of T<span class="Sub">3</span>, T<span class="Sub">4</span>, and TSH.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2><span class="Bold">12.4 Pharmacogenomics</span></h2>
<p class="First">CYP2C19 displays a known genetic polymorphism due to its deficiency in some subpopulations (e.g., approximately 3% of Caucasians and African-Americans and 17% to 23% of Asians are poor metabolizers). Although these subpopulations of pantoprazole poor metabolizers have elimination half-life values of 3.5 to 10 hours in adults, they still have minimal accumulation (â‰¤ 23%) with once-daily dosing. For adult patients who are CYP2C19 poor metabolizers, no dosage adjustment is needed.</p>
<p>Similar to adults, pediatric patients who have the poor metabolizer genotype of CYP2C19 (CYP2C19 *2/*2) exhibited greater than a 6 fold increase in AUC compared to pediatric extensive (CYP2C19 *1/*1) and intermediate (CYP2C19 *1/*x) metabolizers. Poor metabolizers exhibited approximately 10 fold lower apparent oral clearance compared to extensive metabolizers.</p>
<p>For known pediatric poor metabolizers, a dose reduction should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1> 13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="NONCLINICALTOXICOLOGYCARCINOGENESISANDMUTAGENESISANDIMPAIRMENTOFFERTILITY"></a><a name="section-12.1"></a><p></p>
<h2><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </span></h2>
<p class="First">In a 24 month carcinogenicity study, Sprague-Dawley rats were treated orally with doses of 0.5 to 200 mg/kg/day, about 0.1 to 40 times the exposure on a body surface area basis of a 50 kg person dosed at 40 mg/day. In the gastric fundus, treatment at 0.5 to 200 mg/kg/day produced enterochromaffin-like (ECL) cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and benign and malignant neuroendocrine cell tumors in a dose-related manner. In the forestomach, treatment at 50 and 200 mg/kg/day (about 10 and 40 times the recommended human dose on a body surface area basis) produced benign squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> and malignant squamous cell carcinomas. Rare gastrointestinal tumors associated with pantoprazole treatment included an adenocarcinoma of the duodenum at 50 mg/kg/day and benign <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and adenocarcinomas of the gastric fundus at 200 mg/kg/day. In the liver, treatment at 0.5 to 200 mg/kg/day produced dose-related increases in the incidences of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas. In the thyroid gland, treatment at 200 mg/kg/day produced increased incidences of follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas for both male and female rats.</p>
<p>In a 24 month carcinogenicity study, Fischer 344 rats were treated orally with doses of 5 to 50 mg/kg/day, approximately 1 to 10 times the recommended human dose based on body surface area. In the gastric fundus, treatment at 5 to 50 mg/kg/day produced enterochromaffin-like (ECL) cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and benign and malignant neuroendocrine cell tumors. Dose selection for this study may not have been adequate to comprehensively evaluate the carcinogenic potential of pantoprazole.</p>
<p>In a 24 month carcinogenicity study, B6C3F1 mice were treated orally with doses of 5 to 150 mg/kg/day, 0.5 to 15 times the recommended human dose based on body surface area. In the liver, treatment at 150 mg/kg/day produced increased incidences of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas in female mice. Treatment at 5 to 150 mg/kg/day also produced gastric-fundic ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>.</p>
<p>A 26 week p53 +/- transgenic mouse carcinogenicity study was not positive.</p>
<p>Pantoprazole was positive in the <span class="Italics">in vitro</span> human lymphocyte chromosomal aberration assays, in one of two mouse micronucleus tests for clastogenic effects, and in the<span class="Italics"> in vitro</span> Chinese hamster ovarian cell/HGPRT forward mutation assay for mutagenic effects. Equivocal results were observed in the <span class="Italics">in vivo</span> rat liver DNA covalent binding assay. Pantoprazole was negative in the in vitro Ames mutation assay, the in vitro unscheduled DNA synthesis (UDS) assay with rat hepatocytes, the <span class="Italics">in vitro</span> AS52/GPT mammalian cell-forward gene mutation assay, the in vitro thymidine kinase mutation test with mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> L5178Y cells, and the in vivo rat bone marrow cell chromosomal aberration assay.</p>
<p>There were no effects on fertility or reproductive performance when pantoprazole was given at oral doses up to 500 mg/kg/day in male rats (98 times the recommended human dose based on body surface area) and 450 mg/kg/day in female rats (88 times the recommended human dose based on body surface area).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="NONCLINICALTOXICOLOGYANIMALPHARMACOLOGYANDORTOXICOLOGY"></a><a name="section-12.2"></a><p></p>
<h2><span class="Bold">13.2 Animal Toxicology and/or Pharmacology </span></h2>
<p class="First">Studies in neonatal/juvenile and adult rats and dogs were performed. The data from these studies revealed that animals in both age groups respond to pantoprazole in a similar manner. Gastric alterations, including increased stomach weights, increased incidence of eosinophilic chief cells in adult and neonatal/juvenile rats, and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of chief cells in adult rats and in neonatal/juvenile dogs, were observed in the fundic mucosa of stomachs in repeated-dose studies. Decreases in red cell <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> parameters, increases in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides, increased liver weight, enzyme induction, and hepatocellular <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> were also seen in repeated-dose studies in rats and/or dogs. Full to partial recovery of these effects were noted in animals of both age groups following a recovery period.</p>
<p><span class="Bold">Reproductive Toxicology Studies</span></p>
<p>Reproduction studies have been performed in rats at oral doses up to 450 mg/kg/day (88 times the recommended human dose based on body surface area) and rabbits at oral doses up to 40 mg/kg/day (16 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to pantoprazole.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1> 14 CLINICAL STUDIES</h1>
<p class="First">Pantoprazole sodium delayed-release tablets were used in the following clinical trials.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2><span class="Bold">14.1 <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> (EE) Associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) </span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<h3>Adult Patients </h3>
<p class="First">A U.S. multicenter, double-blind, placebo-controlled study of pantoprazole 10 mg, 20 mg, or 40 mg once daily was conducted in 603 patients with reflux symptoms and endoscopically diagnosed EE of grade 2 or above (Hetzel-Dent scale). In this study, approximately 25% of enrolled patients had severe EE of grade 3, and 10% had grade 4. The percentages of patients healed (per protocol, n = 541) in this study are shown in Table 7.</p>
<a name="t6"></a><table>
<caption><span>Table 7: <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Healing Rates (Per Protocol)</span></caption>
<thead><tr class="First Last">
<td></td>
<td>Pantoprazole</td>
<td>Placebo</td>
</tr></thead>
<tbody>
<tr class="First">
<td>Week</td>
<td>10 mg daily<br>(n = 153)</td>
<td>20 mg daily<br>(n = 158)</td>
<td>40 mg daily<br>(n = 162)</td>
<td>(n = 68)</td>
</tr>
<tr>
<td>4</td>
<td>45.6%+</td>
<td>58.4%+#</td>
<td>75%+*</td>
<td>14.3%</td>
</tr>
<tr class="Last">
<td>8</td>
<td>66%+</td>
<td>83.5 %+#</td>
<td>92.6%+*</td>
<td>39.7%</td>
</tr>
</tbody>
</table>
<p>+(p &lt; 0.001) pantoprazole versus placebo</p>
<p>*(p &lt; 0.05) versus 10 mg or 20 mg pantoprazole</p>
<p># (p &lt; 0.05) versus 10 mg pantoprazole</p>
<p></p>
<p>In this study, all pantoprazole treatment groups had significantly greater healing rates than the placebo group. This was true regardless of <span class="Italics">H. pylori</span> status for the 40 mg and 20 mg pantoprazole treatment groups. The 40 mg dose of pantoprazole resulted in healing rates significantly greater than those found with either the 20 mg or 10 mg dose.</p>
<p>A significantly greater proportion of patients taking pantoprazole 40 mg experienced complete relief of daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and the absence of <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span>, starting from the first day of treatment, compared with placebo. Patients taking pantoprazole consumed significantly fewer antacid tablets per day than those taking placebo.</p>
<p>Pantoprazole 40 mg and 20 mg once daily were also compared with nizatidine 150 mg twice daily in a U.S. multicenter, double-blind study of 243 patients with reflux symptoms and endoscopically diagnosed EE of grade 2 or above. The percentages of patients healed (per protocol, n = 212) are shown in Table 8.</p>
<a name="t7"></a><table>
<caption><span>Table 8: <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Healing Rates (Per Protocol)</span></caption>
<thead><tr class="First Last">
<td></td>
<td>Pantoprazole</td>
<td>Nizatidine</td>
</tr></thead>
<tbody>
<tr class="First">
<td>Week</td>
<td>20 mg daily<br>(n = 72)</td>
<td>40 mg daily<br>(n = 70)</td>
<td>150 mg twice daily<br>(n = 70)</td>
</tr>
<tr>
<td>4</td>
<td>61.4%+</td>
<td>64%+</td>
<td>22.2%</td>
</tr>
<tr class="Last">
<td>8</td>
<td>79.2%+</td>
<td>82.9%+</td>
<td>41.4%</td>
</tr>
</tbody>
</table>
<p>+(p &lt; 0.001) pantoprazole versus nizatidine </p>
<p>Once-daily treatment with pantoprazole 40 mg or 20 mg resulted in significantly superior rates of healing at both 4 and 8 weeks compared with twice-daily treatment with 150 mg of nizatidine. For the 40 mg treatment group, significantly greater healing rates compared to nizatidine were achieved regardless of the H. pylori status.</p>
<p>A significantly greater proportion of the patients in the pantoprazole treatment groups experienced complete relief of nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span>, starting on the first day and of daytime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> on the second day, compared with those taking nizatidine 150 mg twice daily. Patients taking pantoprazole consumed significantly fewer antacid tablets per day than those taking nizatidine.</p>
<p><span class="Underline">Pediatric Patients Ages 5 Years through 16 Years</span><br>The efficacy of pantoprazole in the treatment of EE associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in pediatric patients ages 5 years through 16 years is extrapolated from adequate and well-conducted trials in adults, as the pathophysiology is thought to be the same. Four pediatric patients with endoscopically diagnosed EE were studied in multicenter, randomized, double-blind, parallel-treatment trials. Children with endoscopically diagnosed EE (defined as an endoscopic Hetzel-Dent score â‰¥ 2) were treated once daily for 8 weeks with one of two dose levels of pantoprazole (20 mg or 40 mg). All 4 patients with EE were healed (Hetzel-Dent score of 0 or 1) at 8 weeks.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2><span class="Bold">14.2 Long-Term Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></h2>
<p class="First">Two independent, multicenter, randomized, double-blind, comparator-controlled trials of identical design were conducted in adult <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> patients with endoscopically confirmed healed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> to demonstrate efficacy of pantoprazole in long-term maintenance of healing. The two U.S. studies enrolled 386 and 404 patients, respectively, to receive either 10 mg, 20 mg, or 40 mg of pantoprazole sodium delayed-release tablets once daily or 150 mg of ranitidine twice daily. As demonstrated in Table 9, pantoprazole 40 mg and 20 mg were significantly superior to ranitidine at every timepoint with respect to the maintenance of healing. In addition, pantoprazole 40 mg was superior to all other treatments studied.</p>
<a name="t8"></a><table>
<caption><span>Table 9: Long-Term Maintenance of Healing of Erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Maintenance): Percentage of Patients Who Remained Healed </span></caption>
<thead><tr class="First Last">
<td></td>
<td align="center">
<span class="Bold">PantoprazoleÂ  Â Â Â Â Â Â Â Â Â  </span><br><span class="Bold">20 mg daily</span>
</td>
<td align="center">
<span class="Bold">PantoprazoleÂ  Â Â Â Â Â Â Â Â Â  </span><br><span class="Bold">40 mg daily</span>
</td>
<td align="center">
<span class="Bold">Ranitidine Â  </span><br><span class="Bold">150 mg twice daily</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td><span class="Bold">Study 1</span></td>
<td align="center">n = 75</td>
<td align="center">n = 74</td>
<td align="center">n = 75</td>
</tr>
<tr>
<td>Month 1</td>
<td align="center">91*</td>
<td align="center">99*</td>
<td align="center">68</td>
</tr>
<tr>
<td>Month 3</td>
<td align="center">82*</td>
<td align="center">93*#</td>
<td align="center">54</td>
</tr>
<tr>
<td>Month 6</td>
<td align="center">76*</td>
<td align="center">90*#</td>
<td align="center">44</td>
</tr>
<tr>
<td>Month 12</td>
<td align="center">70*</td>
<td align="center">86*#</td>
<td align="center">35</td>
</tr>
<tr>
<td><span class="Bold">Study 2</span></td>
<td align="center">n = 74</td>
<td align="center">n = 88</td>
<td align="center">n = 84</td>
</tr>
<tr>
<td>Month 1</td>
<td align="center">89*</td>
<td align="center">92*#</td>
<td align="center">62</td>
</tr>
<tr>
<td>Month 3</td>
<td align="center">78*</td>
<td align="center">91*#</td>
<td align="center">47</td>
</tr>
<tr>
<td>Month 6</td>
<td align="center">72*</td>
<td align="center">88*#</td>
<td align="center">39</td>
</tr>
<tr class="Last">
<td>Month 12</td>
<td align="center">72*</td>
<td align="center">83*</td>
<td align="center">37</td>
</tr>
</tbody>
</table>
<p>*(p &lt; 0.05 vs. ranitidine)</p>
<p># (p &lt; 0.05 vs. pantoprazole 20 mg)</p>
<p>Note: Pantoprazole 10 mg was superior (p &lt; 0.05) to ranitidine in Study 2, but not Study 1.</p>
<p>Pantoprazole 40 mg was superior to ranitidine in reducing the number of daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> episodes from the first through the twelfth month of treatment. Pantoprazole 20 mg, administered once daily, was also effective in reducing episodes of daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> in one trial, as presented in Table 10.</p>
<a name="t9"></a><table>
<caption><span>Table 10: Number of Episodes of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span> (mean Â± SD)</span></caption>
<thead><tr class="First Last">
<td></td>
<td align="center"></td>
<td align="center">
<span class="Bold"> Pantoprazole </span><br><span class="Bold">40 mg daily</span>
</td>
<td align="center">
<span class="Bold">Ranitidine</span><br><span class="Bold">150 mg twice daily</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td>Month 1</td>
<td>Daytime<br>Nighttime</td>
<td align="center">
<p class="First">5.1 Â± 1.6*</p>3.9 Â± 1.1*</td>
<td align="center">
<p class="First">18.3 Â± 1.6</p>11.9 Â± 1.1</td>
</tr>
<tr class="Last">
<td>Month 12</td>
<td>Daytime<br>Nighttime</td>
<td align="center">
<p class="First">2.9 Â± 1.5*</p>
<p>2.5 Â± 1.2*</p>
</td>
<td align="center">
<p class="First">17.5 Â± 1.5</p>13.8 Â± 1.3</td>
</tr>
</tbody>
</table>
<p>*(p &lt; 0.001 vs. ranitidine, combined data from the two U.S. studies)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2><span class="Bold">14.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome </span></h2>
<p class="First">In a multicenter, open-label trial of 35 patients with pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, with or without <span class="product-label-link" type="condition" conceptid="30678" conceptname="Polyglandular activity in multiple endocrine adenomatosis">multiple endocrine neoplasia</span>-type I, pantoprazole successfully controlled gastric acid secretion. Doses ranging from 80 mg daily to 240 mg daily maintained gastric acid output below 10 mEq/h in patients without prior acid-reducing surgery and below 5 mEq/h in patients with prior acid-reducing surgery.</p>
<p>Doses were initially titrated to the individual patient needs, and adjusted in some patients based on the clinical response with timeÂ [<span class="Italics">see Dosage and Administration (<a href="#DOSAGE_AND_ADMINISTRATION">2</a></span>)]. Pantoprazole was well tolerated at these dose levels for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> (greater than 2 years in some patients).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1> 16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">How Supplied</span></p>
<p>Pantoprazole sodium delayed-release tablets, USP are supplied as 40 mg yellow colored, oval shaped, enteric coated tablets imprinted with â€œ40â€? on one side and plain on the other side and are available as follows:</p>
<p>NDC 42043-371-90, bottles of 90<br>NDC 42043-371-01, bottles of 100</p>
<p>Pantoprazole sodium delayed-release tablets, USP are supplied as 20 mg yellow colored, oval shaped, enteric coated tablets imprinted with â€œ20â€? on one side and plain on the other side and are available as follows:</p>
<p>NDC 42043-370-90, bottles of 90</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Bold">Storage </span></span></p>
<p>Store pantoprazole sodium delayed-release tablets, USP at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) <span class="Italics">[see USP Controlled Room Temperature]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17. PATIENT COUNSELING INFORMATION</span></h1>
<p class="First"><span class="Italics">See FDA-Approved Medication Guide</span></p>
<ul>
<li>Caution patients that pantoprazole sodium delayed-release tablets should not be split, crushed, or chewed.</li>
<li>Tell patients that pantoprazole sodium delayed-release tablets should be swallowed whole, with or without food in the stomach.</li>
<li>Let patients know that concomitant administration of antacids does not affect the absorption of pantoprazole sodium delayed-release tablets.</li>
<li>Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> as these may be signs of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> <span class="Italics">[see Warnings and Precautions (5.7)]</span>.<span class="Italics"></span>
</li>
<li>Advise patients to immediately report and seek care for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not improve. This may be a sign of <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><span class="Italics"> [see Warnings and Precautions (5.5)].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-16"></a><p></p>
<h1><span class="Bold">Medication Guide</span></h1>
<p class="First"><span class="Bold">Pantoprazole Sodium (pan-TOE-pra-zole SOE-dee-um) Delayed-Release Tablets, USP</span></p>
<p>Read this Medication Guide before you start taking pantoprazole sodium delayed-release tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about pantoprazole sodium delayed-release tablets?</span></p>
<p><span class="Bold">Pantoprazole sodium delayed-release tablets may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.</span></p>
<p><span class="Bold">Pantoprazole sodium delayed-release tablets can cause serious side effects, including:</span></p>
<ul><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span>. Pantoprazole sodium delayed-release tablets may increase your risk of getting severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. This <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be caused by an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">(Clostridium difficile)</span> in your intestines.</li></ul>
<p>Call your doctor right away if you have watery stool, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> that does not go away.</p>
<p></p>
<ul><li>
<span class="Bold">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></span>. People who take multiple daily doses of proton pump inhibitor medicines for a long period of time (a year or longer) may have an increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist or spine. You should take pantoprazole sodium delayed-release tablets exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your doctor about your risk of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> if you take pantoprazole sodium delayed-release tablets.</li></ul>
<p>Pantoprazole sodium delayed-release tablets can have other serious side effects. See <span class="Bold">"What are the possible side effects of pantoprazole sodium delayed-release tablets?â€?</span></p>
<p><span class="Bold">What are pantoprazole sodium delayed-release tablets?</span></p>
<p>Pantoprazole sodium delayed-release tablets are a prescription medicine called a proton pump inhibitor (PPI).</p>
<p>Pantoprazole sodium delayed-release tablets reduce the amount of acid in your stomach.</p>
<p>Pantoprazole sodium delayed-release tablets are used in adults:</p>
<ul>
<li>for up to 8 weeks to heal acid-related damage to the lining of the esophagus (<span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> or EE) and to relieve symptoms caused by <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>). If needed, your doctor may decide to prescribe another 8 weeks of pantoprazole sodium delayed-release tablets.</li>
<li>to maintain the healing of acid-related damage to the lining of the esophagus and help prevent return of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> symptoms caused by <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. It is not known if pantoprazole sodium delayed-release tablets are safe and effective if used longer than 12 months (1 year). <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> happens when acid in your stomach backs up into the tube (esophagus) that connects your mouth to your stomach. This may cause a burning feeling in your chest or throat, sour taste, or burping.</li>
<li>for the long-term treatment of conditions where your stomach makes too much acid. This includes a rare condition called Zollinger-Ellison syndrome.</li>
</ul>
<p>Pantoprazole sodium delayed-release tablets are used in children 5 years of age and older for up to 8 weeks to heal acid-related damage to the lining of the esophagus (<span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> or EE) caused by <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>.</p>
<p>It is not known if pantoprazole sodium delayed-release tablets are safe if used longer than 8 weeks in children. Pantoprazole sodium delayed-release tablets are not for use in children under 5 years of age.</p>
<p><span class="Bold">Who should not take pantoprazole sodium delayed-release tablets?</span></p>
<p>Do not take pantoprazole sodium delayed-release tablets if you are:</p>
<ul>
<li>allergic to pantoprazole sodium or any of the other ingredients in pantoprazole sodium delayed-release tablets. See the end of this Medication Guide for a complete list of ingredients in pantoprazole sodium delayed-release tablets.</li>
<li>allergic to any proton pump inhibitor (PPI) medicine.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking pantoprazole sodium delayed-release tablets?</span></p>
<p><span class="Bold">Before taking pantoprazole sodium delayed-release tablets, tell your doctor if you:</span></p>
<ul>
<li>have been told that you have low magnesium levels in your blood</li>
<li>have liver problems</li>
<li>have any other medical conditionsare pregnant or plan to become pregnant. It is not known if pantoprazole sodium delayed-release tablets will harm your unborn baby.</li>
<li>are breastfeeding or plan to breastfeed. Pantoprazole sodium may pass into your milk. You and your doctor should decide if you will take pantoprazole sodium delayed-release tablets or breastfeed. You should not do both. Talk with your doctor about the best way to feed your baby if you take pantoprazole sodium delayed-release tablets.</li>
</ul>
<p><span class="Bold">Tell your doctor about all of the medicines you take,</span> including prescription and non-prescription drugs, vitamins and herbal supplements. Pantoprazole sodium delayed-release tablets may affect how other medicines work, and other medicines may affect how pantoprazole sodium delayed-release tablets work.</p>
<p>Especially tell your doctor if you take:</p>
<ul>
<li>atazanavir (Reyataz)</li>
<li>nelfinavir (Viracept)</li>
<li>warfarin (Coumadin, Jantoven)</li>
<li>ketoconazole (Nizoral)</li>
<li>a product that contains iron</li>
<li>an antibiotic that contains ampicillin</li>
<li>methotrexate</li>
<li>mycophenolate mofetil (Cellcept)</li>
</ul>
<p>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</p>
<p>Know the medicines that you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take pantoprazole sodium delayed-release tablets?</span></p>
<ul>
<li>Take pantoprazole sodium delayed-release tablets exactly as prescribed by your doctor.</li>
<li>Do not change your dose or stop pantoprazole sodium delayed-release tablets without talking to your doctor.</li>
<li>If you forget to take a dose of pantoprazole sodium delayed-release tablets, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose at your regular time. Do not take two doses to try to make up for a missed dose.</li>
<li>If you take too much pantoprazole sodium delayed-release tablets, call your doctor right away or go to the nearest hospital emergency room.</li>
<li>See the Instructions for Use at the end of this Medication Guide for detailed instructions about how to take pantoprazole sodium delayed-release tablets.</li>
</ul>
<p><span class="Bold">What are the possible side effects of pantoprazole sodium delayed-release tablets?</span></p>
<p><span class="Bold">Pantoprazole sodium delayed-release tablets may cause serious side effects, including:</span></p>
<p><span class="Bold">See â€œWhat is the most important information I should know about pantoprazole sodium delayed-release tablets?â€?</span></p>
<ul>
<li>
<span class="Bold">Chronic (lasting a long time) <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the lining of the stomach (<span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic Gastritis</span>).</span> Taking pantoprazole sodium delayed-release tablets for a long period of time may increase the risk of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> to your stomach lining. You may or may not have symptoms. Tell your doctor if you have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</li>
<li>
<span class="Bold">Vitamin B-12 deficiency.</span> Pantoprazole sodium delayed-release tablets reduce the amount of acid in your stomach. Stomach acid is needed to absorb vitamin B-12 properly. Talk with your doctor about the possibility of vitamin B-12 deficiency if you have been on pantoprazole sodium delayed-release tablets for a long time (more than 3 years).</li>
<li>
<span class="Bold">Low magnesium levels in your body.</span> This problem can be serious. Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment. You may or may not have symptoms of low magnesium.</li>
</ul>
<p>Tell your doctor right away if you have any of these symptoms:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>abnormal or fast heartbeat</li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span></li>
<li>jerking movements or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the hands and feet</li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li>spasm of the voice box</li>
</ul>
<p>Your doctor may check the level of magnesium in your body before you start taking pantoprazole sodium delayed-release tablets or during treatment, if you will be taking pantoprazole sodium delayed-release tablets for a long period of time.</p>
<p>The most common side effects with pantoprazole sodium delayed-release tablets in adults include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li>Gas</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in your joints</li>
</ul>
<p>The most common side effects with pantoprazole sodium delayed-release tablets in children include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Stomach pain</span></li>
</ul>
<p>Other side effects:</p>
<ul>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span>. Tell your doctor if you get any of the following symptoms with pantoprazole sodium delayed-release tablets:</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>face <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span></li>
<li>difficult breathing</li>
</ul>
<p>Your doctor may stop pantoprazole sodium delayed-release tablets if these symptoms happen.</p>
<p>Tell your doctor about any side effects that bother you or that do not go away.</p>
<p>These are not all the possible side effects with pantoprazole sodium delayed-release tablets. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store pantoprazole sodium delayed-release tablets?</span></p>
<ul><li>Store pantoprazole sodium delayed-release tablets at room temperature between 68Â° to 77Â°F (20Â° to 25Â°C).</li></ul>
<p><span class="Bold">Keep pantoprazole sodium delayed-release tablets and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about pantoprazole sodium delayed-release tablets</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use pantoprazole sodium delayed-release tablets for a condition for which they were not prescribed. Do not give pantoprazole sodium delayed-release tablets to other people, even if they have the same symptoms you have. They may harm them.</p>
<p>This Medication Guide summarizes the most important information about pantoprazole sodium delayed-release tablets. For more information, ask your doctor. You can ask your doctor or pharmacist for information that is written for healthcare professionals.</p>
<p>For more information, call PROSAR at 866-562-4590.</p>
<p><span class="Bold">What are the ingredients in pantoprazole sodium delayed-release tablets?</span></p>
<p><span class="Bold">Active ingredient:</span> pantoprazole sodium sesquihydrate</p>
<p><span class="Bold">Inactive ingredients in pantoprazole sodium delayed-release tablets:</span> calcium stearate, crospovidone, hydroxypropyl cellulose, hypromellose, mannitol, methacrylic acid co-polymer dispersion, opacode black, opadry yellow, sodium carbonate, talc, and triethyl citrate.</p>
<p>The components of opacode black are ammonium hydroxide, iron oxide black, isopropyl alcohol, n-butyl alcohol, propylene glycol and shellac glaze in ethanol, and the components of opadry yellow are hypromellose, iron oxide yellow, polyethylene glycol 6000 and titanium dioxide.</p>
<p><span class="Bold">Instructions for Use</span></p>
<ul>
<li>You can take pantoprazole sodium delayed-release tablets with food or on an empty stomach.</li>
<li>Swallow pantoprazole sodium delayed-release tablets whole.</li>
<li>If you have trouble swallowing a pantoprazole sodium delayed-release tablet 40 mg, you can take two 20 mg tablets instead.</li>
<li>Do not split, chew, or crush pantoprazole sodium delayed-release tablets.</li>
</ul>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by: Orchid Healthcare<br>(A Division of Orchid Chemicals &amp;<br>Pharmaceuticals Ltd.)<br>Irungattukottai - 602 105, India</p>
<p>Manufactured for: OrchidPharma, Inc.<br>Princeton, NJ 08540, USA</p>
<p><span class="Bold">I</span>01/2015<br>948026418</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1> PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"></p>
<p>OrchidPharma</p>
<p>NDC 42043-370-09</p>
<p>Pantoprazole-Sodium Delayed Release Tablets, USP</p>
<p>20 mg</p>
<p>90 Tablets</p>
<p>Rx only</p>
<p></p>
<p><span class="Bold"><img alt="label1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d132d29d-723e-4357-87f2-0d760afa50a4&amp;name=pantoprazole-sodium--figure-2.jpg"></span></p>
<p></p>
<p>OrchidPharma</p>
<p>NDC 42043-371-09</p>
<p>Pantoprazole-Sodium Delayed Release Tablets, USP</p>
<p>40 mg</p>
<p>90 Tablets</p>
<p>Rx only</p>
<br><p><img alt="label2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d132d29d-723e-4357-87f2-0d760afa50a4&amp;name=pantoprazole-sodium--figure-3.jpg"></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PANTOPRAZOLE SODIUMÂ 		
					</strong><br><span class="contentTableReg">pantoprazole sodium tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42043-370</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANTOPRAZOLE SODIUM</strong> (PANTOPRAZOLE) </td>
<td class="formItem">PANTOPRAZOLE</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CARBONATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE E)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOBUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42043-370-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202052</td>
<td class="formItem">03/20/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PANTOPRAZOLE SODIUMÂ 		
					</strong><br><span class="contentTableReg">pantooprazole sodium tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42043-371</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANTOPRAZOLE SODIUM</strong> (PANTOPRAZOLE) </td>
<td class="formItem">PANTOPRAZOLE</td>
<td class="formItem">40Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CARBONATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE E)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOBUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">40</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42043-371-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:42043-371-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202052</td>
<td class="formItem">03/20/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>OrchidPharma Inc
							(809429207)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c8357a86-a7b1-4811-9251-5a7c4ef05939</div>
<div>Set id: d132d29d-723e-4357-87f2-0d760afa50a4</div>
<div>Version: 2</div>
<div>Effective Time: 20150211</div>
</div>
</div>Â <div class="DistributorName">OrchidPharma Inc</div></p>
</body></html>
